The price of Seres Therapeutics Inc. (NASDAQ:MCRB) shares last traded on Wall Street rose 1.45% to $3.50.
Based on available information, 7 analysts follow Seres Therapeutics Inc. (NASDAQ:MCRB). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $15.00 and a low of $4.00, we find $11.00. Given the previous closing price of $3.45, this indicates a potential upside of 218.84 percent. MCRB stock price is now -27.64% away from the 50-day moving average and -37.12% away from the 200-day moving average. The market capitalization of the company currently stands at $455.63M.
Among analysts, 1 rate the stock a hold while 5 rate it a buy. Brokers who have rated the stock have averaged $9.83 as their price target over the next twelve months.
In other news, Ege David S., insider sold 7,038 shares of the company’s stock on Apr 28. The stock was sold for $36,527 at an average price of $5.19. Upon completion of the transaction, the insider now directly owns 59,696 shares in the company, valued at $0.21 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Oct 31, Ege David S. sold 5,012 shares of the business’s stock. A total of $39,745 was realized by selling the stock at an average price of $7.93. This leaves the insider owning 46,734 shares of the company worth $0.16 million. Insiders disposed of 12,050 shares of company stock worth roughly $42175.0 over the past 1 year. A total of 0.50% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in MCRB stock. A new stake in Seres Therapeutics Inc. shares was purchased by SOLEUS CAPITAL MANAGEMENT, L.P. during the first quarter worth $7,161,000. GREAT POINT PARTNERS I LP invested $3,283,000 in shares of MCRB during the first quarter. In the first quarter, EXODUSPOINT CAPITAL MANAGEMENT, LP acquired a new stake in Seres Therapeutics Inc. valued at approximately $2,082,000. UNISUPER MANAGEMENT PTY LTD acquired a new stake in MCRB for approximately $1,454,000. WOODLINE PARTNERS LP purchased a new stake in MCRB valued at around $853,000 in the second quarter. In total, there are 188 active investors with 85.80% ownership of the company’s stock.
A candlestick chart of Seres Therapeutics Inc. (NASDAQ: MCRB) showed a price of $3.5100 on Thursday morning. During the past 12 months, Seres Therapeutics Inc. has had a low of $3.45 and a high of $9.49. As of last week, the company has a debt-to-equity ratio of 4.46, a current ratio of 3.20, and a quick ratio of 3.20. The fifty day moving average price for MCRB is $4.8120 and a two-hundred day moving average price translates $5.5433 for the stock.
The latest earnings results from Seres Therapeutics Inc. (NASDAQ: MCRB) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at $0.36, missing analysts’ expectations of $0.53 by -0.17. This compares to -$0.70 EPS in the same period last year. The company reported revenue of $126.47 million for the quarter, compared to $1.22 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 10300.74 percent. For the current quarter, analysts expect MCRB to generate $1.87M in revenue.
Seres Therapeutics Inc.(MCRB) Company Profile
Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company’s lead product candidate is SER-109, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes SER-109 product candidate, which is developed for the treatment of CDI and recurrent CDI; collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn’s disease; research collaboration and option agreement with AstraZeneca Inc. for research and develop of microbiome in certain cancers and cancer immunotherapies, including research program for SER-401 targeting various cancers. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
